文献速递肿瘤 PET/CT

99mTc-PSMA SPECT/CT与68Ga-PSMA PET/CT在转移性前列腺癌评估中的比较

99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该研究纳入22例确诊或疑似转移性前列腺癌患者,对比99mTc-PSMA SPECT/CT与68Ga-PSMA PET/CT的评估价值。患者水平两者阳性率均为95.45%(21/22);区域水平PET/CT检出53个区域,SPECT/CT检出43个,差异主要源于前列腺床检出率较低(n=6)。结论认为99mTc-PSMA SPECT/CT可作为高危患者的潜在替代,但需关注前列腺床评估。

要点

  • 患者水平99mTc-PSMA SPECT/CT与68Ga-PSMA PET/CT阳性率一致,均为95.45%。
  • 区域水平PET/CT检出更多受累区域(53 vs 43,P=0.007)。
  • SPECT/CT前列腺床检出率较低(n=6),是主要差异来源。

核心结论

  • 99mTc-PSMA SPECT/CT可能作为高危前列腺癌患者中68Ga-PSMA PET/CT的潜在替代,但前列腺床评估为主要顾虑时除外。

研究设计与样本

  • 研究纳入22例确诊或疑似转移性前列腺癌患者,平均年龄66.6±10.1岁,均行99mTc-PSMA SPECT/CT与68Ga-PSMA PET/CT,两次显像间隔小于7天。
  • 68Ga-PSMA PET/CT于静脉注射185 MBq(5 mCi)后60分钟行全身PET/CT;99mTc-PSMA SPECT/CT于静脉注射555-740 MBq(15-20 mCi)后3小时进行。
  • 两种模态图像独立判读,并按患者水平和区域水平进行比较分析。

主要发现

  • 患者水平评估中,99mTc-PSMA SPECT/CT与68Ga-PSMA PET/CT均为95.45%(21/22)阳性。
  • 区域水平评估中,68Ga-PSMA PET/CT检出53个区域(每例中位数2个,范围0-5),99mTc-PSMA SPECT/CT检出43个区域(每例中位数2个,范围0-5)。
  • 差异主要可由99mTc-PSMA SPECT/CT对前列腺床的检出率较低解释(n=6)。
  • PET/CT检测到的受累区域多于SPECT/CT(P=0.007),而两种模态诊断前列腺外病变的频率相似(P=0.102)。
  • 血清前列腺特异性抗原水平与两种模态检测的疾病扩展影像学参数之间存在显著相关性。

临床怎么用

  • 在高危前列腺癌患者中,可考虑使用99mTc-PSMA SPECT/CT作为68Ga-PSMA PET/CT的潜在替代,但当前列腺床评估为主要关注点时不宜替代。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 99mTc-prostate-specific membrane antigen (PSMA) SPECT/CT is less expensive and readily available modality compared with 68Ga-PSMA PET/CT for imaging prostate cancer (PC). The aim of this study is to compare the value of these 2 modalities in patients confirmed or suspicious to have metastatic prostate cancer. PATIENTS AND METHODS: Twenty-two patients with the mean age of 66.6 ± 10.1 years were studied using 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT, with less than 7 days interval between the 2 imaging procedures. Whole-body PET/CT was done 60 minutes after IV injection of 185 MBq (5 mCi) of 68Ga-PSMA. 99mTc-PSMA SPECT/CT was performed 3 hours after IV injection of 555 to 740 MBq (15-20 mCi) of 99mTc-PSMA. The images of each modality were interpreted independently, and the results were compared according to patient-based as well as region-based analyses. RESULTS: In patient-based evaluation, both 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT scans were positive in 95.45% (21/22). In region-based evaluation, 68Ga-PSMA PET/CT detected 53 regions (median of 2 regions per patient; range, 0-5), whereas 43 (median of 2 regions per patient; range, 0-5) were detected by 99mTc-PSMA SPECT/CT. Most of these differences could be explained by lower detection rate of 99mTc-PSMA SPECT/CT in prostate bed (n = 6). PET/CT detected more involved regions than SPECT/CT (P = 0.007), whereas similar frequency of extraprostatic lesions were diagnosed in both modalities (P = 0.102). Significant correlation was also demonstrated between serum prostate-specific antigen level and imaging parameters of disease extension detected by 2 modalities. CONCLUSIONS: 99mTc-PSMA SPECT/CT could be a potential substitute for 68Ga-PSMA PET/CT in high-risk patients, except when evaluation of prostate bed is of major concern.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fallahi B, Khademi N, Karamzade-Ziarati N, et al. 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer. Clin Nucl Med. 2021. PMID: 33234922. doi:10.1097/RLU.0000000000003410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。